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Abstract 
The present studies describe the biodistribution of cationic liposomes and cationic liposome/oligonucleotide complex following 
intravenous injection into mice via the tail vein. t llIn-diethylenetriaminepentaacetic id stearylamide (~In-DTPA-SA) was used as a 
lipid-phase radiolabel. Inclusion of up to 5 mol% DTPA-SA in liposomes composed of 3~-(N-(N',N'-dimethylamino- 
ethane)carbamoyl)cholesterol (DC-Chol) and dioleoylphosphatidylethanolamine (DOPE) did not influence liposome formation or size, nor 
the binding/uptake or fusion of the cationic liposomes with CHO cells in vitro. Moreover, nuclear delivery of oligonucleotide to CHO 
cells was unaffected by the probe. The biodistribution f liposomes with increasing concentration f DC-Chol (1:4-4:1, DC-Chol/DOPE, 
mol/mol) at 24 h post-injection revealed no dependence on lipid composition. Uptake was primarily by liver, and accumulation i  spleen 
and skin was also observed. Comparatively little accumulation occurred in lung. Clearance of injected liposomes by liver was very rapid 
( ~ 84.5% of the injected ose by 7.5 h post-injection). Liposome uptake by liver and spleen were equally efficient in the dose range of 
3.33 to 33.33 mg/kg body weight, yet possible saturation of liver uptake at a dose of 66.80 mg/kg may have allowed for increased 
spleen accumulation. Preincubation of cationic liposomes with phosphorothioate oligonucleotide induced a dramatic yet transient 
accumulation of the lipid in lung which gradually redistributed to liver. Similar results were observed when monitoring iodinated 
oligonucleotide in the complex. Immuno-histochemical studies revealed large aggregates of oligonucleotide within pulmonary capillaries 
at 15 min post-injection, suggesting the early accumulation i lung was due to embolism. Immuno-histochemical studies further evealed 
labeled oligonucleotide to be localized primarily to Kupffer cells at 24 h post-injection. Immuno-electron microscopy revealed 
localization of oligonucleotide primarily to the lumen of pulmonary capillaries at 15 min post-injection, and to phagocytic vacuoles of 
Kupffer cells at 24 h post-injection. By these methods, nuclear delivery of oligonucleotide in vivo was not observed. Increasing 
concentration of mouse serum inhibited cellular binding/uptake of cationic liposomes in vitro, without or with complexed oligonucleo- 
tide. We therefore postulate that interaction with plasma components, including opsonin(s), inhibits cellular uptake of the injected 
liposomes as well as the liposome/oligonucleotide complex, and mediates rapid uptake by Kupffer cells of the liver. These results are 
relevant to the design of cationic liposomes for efficient delivery of nucleic acid in vivo. 
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1. Introduction 
Abbreviations: BrdU, 5-bromodeoxyuridine; CHO, Chinese hamster 
ovary; D-PBS, Dulbecco's phosphate-buffered saline; DC-Chol, 3]3-(N- 
(N',N'-dimethylaminoethane)carbamoyl)cholesterol; DOPE, di- 
oleoylphosphatidylethanolamine; DTPA-SA, diethylenetriaminepen- 
taacetic acid stearylamide; GAR, goat anti-rat; 3H-CE, hexadecyl 
[3H]cholestanyl ether; PS, phosphatidylserine; Pyr-PC, 3-palmitoyl-2-(l- 
pyrenedecanoyl)phosphatidylcholine; SA, st arylamine. 
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Antisense oligonucleotides are in development by sev- 
eral groups with the prospect of arresting the expression of 
specifically targeted genes. The mechanism for such inhi- 
bition may primarily be via RNase hydrolysis of the RNA 
strand of the target mRNA-oligonucleotide duplex. How- 
ever, other mechanisms including transcription inhibition 
following the formation of a DNA-oligonucleotide triplex, 
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and the inhibition of mRNA transport o the cytoplasm 
have been proposed [1]. Efforts to improve the potency of 
antisense oligonucleotides include the synthesis of nucle- 
ase-resistant oligonucleotides. Introduction of phosphoro- 
thioate linkages has been shown to confer nuclease resis- 
tance [2]. Furthermore, circulating phosphorothioated 
oligonucleotides in vivo appear to remain intact for over 
24 h [3]. 
The inability of oligonucleotides to efficiently traverse 
through cellular membranes poses a major obstacle for 
activity. While nuclear delivery of oligonucleotides can be 
achieved in vitro by microinjection, simple incubation of 
the fluorescently-labeled oligonucleotides with cells results 
in accumulation i  cytoplasmic granules and no fluores- 
cence in the nucleus [4]. 
However, cationic liposomes have been shown to 
markedly increase the association of oligonucleotide with 
cells in vitro [5]L Furthermore, oligonucleotide complexed 
with cationic liposomes and subsequently incubated with 
cells localized within the nucleus, as well as to discrete 
structures in the cytoplasm [4,5]. Moreover, cationic lipo- 
somes have been shown to greatly enhance the potency of 
antisense oligonucleotides in vitro [5,6]. 
Liposomes composed of the cationic lipid 3/3-(N- 
(N',N'-dimethylaminoethane)carbamoyl)cholesterol (DC- 
Chol) together with dioleoylphosphatidylethanolamine 
(DOPE) have demonstrated fficient ransfection of cells 
in vitro with plasmid DNA [7]. DC-Chol is stable and has 
low toxicity [7], presumably due to biodegradability. 
Transfection of malignant tumors in vivo by direct injec- 
tion of DC-Chol/DOPE liposome/DNA complex into 
exposed tumor has been demonstrated [8]. DC-Chol/DOPE 
liposomes also mediate nuclear delivery of oligonucleotide 
to cells in vitro (D. Collins, unpublished ata). 
To evaluate the potential of cationic liposomes as a 
reagent for antisense oligonucleotide therapy, we examined 
the biodistribution of cationic liposomes and cationic lipo- 
somes complexed with oligonucleotide in vivo following 
intravenous injection. Our studies demonstrate hat cationic 
liposomes are rapidly cleared by liver. Complexation of 
the liposomes with oligonucleotide induced a dramatic yet 
transient accumulation i lung. Both the lipid and oligo- 
nucleotide were cleared from the lung and subsequently 
accumulated in liver. Immuno-histochemistry and im- 
muno-electron microscopy results suggest he lung accu- 
mulation of the complex is primarily due to embolism, and 
the subsequent liver accumulation is localized primarily to 
the Kupffer cells. By our methods, nuclear delivery of 
oligonucleotide in vivo was not observed. Furthermore, 
our studies show that binding/uptake of cationic lipo- 
somes both alone, or complexed with oligonucleotide, by 
cells in vitro is inhibited by serum. We propose that 
interaction with plasma components, including opsonin(s), 
must be reduced in order for cationic liposomes to be used 
for efficient nuclear delivery of oligonucleotide in vivo. 
2. Materials and methods 
2.1. Materials 
DOPE was purchased from Avanti Polar Lipids 
(Alabaster, AL) and Chol was obtained from Sigma (St. 
Louis, MO). 111INC13 (carrier-free) and 125I were from 
New England Nuclear (Boston, MA). DTPA-SA was syn- 
thesized as described [9], and Ill In-labeled DTPA-SA 
(111In-DTPA-SA) was prepared as described [10]. DC-Chol 
was synthesized as described [7]. CHO D- cells were 
obtained from Dr. G. Trail (Amgen) and were grown in 
RPM! 1640, containing 10% FBS and 1% 
penicillin/streptomycin/glutamine. Pyr-PC was pur- 
chased from Molecular Probes (Eugene, OR). LS2-1, a 
fully phosphorothioated 18mer oligonucleotide, and F15- 
27, a BrdU-labeled analog of LS2-1, were synthesized at 
Amgen Boulder. FITC-labeled phosphorothioated 18mer 
oligonucleotide was also synthesized at Amgen Boulder. 
D-PBS was obtained from Gibco, BRL (Gaithersburg, 
MD). 
2.2. Liposome and liposome/oligonucleotide complex 
preparation 
Lipid mixtures containing trace amounts of ~JlIn- 
DTPA-SA or hexadecyl [3H]cholestanyl ether (3H-CE) 
were dried from organic solvent with N 2 gas and vacuum 
desiccated for 0.5 h using a Savant speedvac desiccator. 
The lipid was then allowed to hydrate in distilled H20 on 
ice overnight. The hydrated lipid films were sonicated in a 
bath-type sonicator (Laboratory Supplies, Hicksville, NY) 
for 10 min, followed by a 10 rain resting period, and an 
additional 10 rain of sonication. Hepes buffer, pH 7.5, was 
then added (20 mM Hepes, 150 mM NaC1 final concentra- 
tion) while vortexing. Cationic liposome/oligonucleotide 
complexes were prepared by adding oligonucleotide, in
Hepes buffer, pH 7.5, to liposomes (final charge ratio 4:1, 
mol DC-Chol/mol nucleotide) while vortexing. Diameter 
measurements of liposomes and liposome/oligonucleotide 
complexes were done using a Malvern 4700c multiangle 
light-scattering instrument. 
2.3. In vitro cell uptake studies 
CHO D- cells were grown in 24-well plates to ~ 80% 
confluency and then washed in serum-free medium. DC- 
Chol/DOPE liposomes (1:1, mol/mol) labeled with 3H- 
CE, and without or with increasing concentration of 
DTPA-SA, and without or with complexed oligonucleo- 
tide, were added to the cells. Serum was isolated from 
female CD-1 mice as described [11]. Samples added in 
serum were preincubated with the serum at 37°C for 5 rain. 
All incubations were done at 37°C for 1 h. Cells were then 
washed three times with serum-free medium and dissolved 
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overnight in 0. l M NaOH. An aliquot from each well was 
assayed for radioactivity by scintillation counting, and the 
protein content of each well was determined by BCA assay 
(Pierce, Rockford, IL). Data are expressed as nmol lipid 
uptake per mg cellular protein. All determinations were 
done in triplicate. 
2.4. Liposome-cell fusion 
Lipid mixing between cationic liposomes and cells was 
assayed as described [12]. Briefly, 80 nmol DC- 
Chol/DOPE liposomes (1:1, mol/mol) labeled with 5 
tool% Pyr-PC were added to 3 ml PBS equilibrated at 
37°C. Trypsinized CHO cells (1. 105 cells) were then 
added, and decreasing pyrene excimer fluorescence (A~ 
343 nm and A~,~ 483 rim, 3 nm slit widths) monitored for 
30 min. At the end of the incubation period, Triton X-100 
was added to a final concentration of 1.0% and excimer 
fluorescence Frx recorded. The extent of lipid mixing was 
calculated using the equation: % maximal ipid mixing = 
100 × (F,, - F)/(F,, - Fv×) where Fo and F are the ex- 
cimer fluorescence intensities before and after the addition 
of cells, respectively. 
2.5. Fluorescence microscopy 
CHO D-  cells were grown on 18 mm round glass 
coverslips to 70-80% confluency. After washing the cells 
with serum-free RPMI 1640 medium, samples were added 
and incubated with the cells at 37°C for 1 h. The cells were 
then washed again with serum-free medium, and fixed in 
1% paraformaldehyde for 20 min at room temperature. 
After a final washing with serum-free medium, the cover- 
slips were mounted onto glass microslides and the cells 
were observed using a Nikon Microphot FX fluorescence 
microscope and a 60 × oil immersion lens. 
2.6. lodination of oligonucleotide 
Oligonucleotide was iodinated as described [13] with 
modification. Briefly, 600 pmol ~25I was added to 100 /xg 
of oligonucleotide LS2-1 in 0.1 mM sodium acetate, pH 
4.0 in a glass tube coated on the bottom with 30 /xg 
Iodogen reagent (Pierce, Rockford, IL). The mixture was 
incubated in a water bath at 50°C for 30 min. Oligonucleo- 
tide was partially reisolated using a Bio-Gel P-4 spin 
column (Bio-Rad, Richmond, CA). Residual unincorpo- 
rated iodine was removed by dialysis against distilled 
water at 4°C overnight using a CE MWCO 500 dialysis 
membrane (Spectrum, Houston, TX). Purity of the final 
sample was determined by thin layer chromatography on
PEI-cellulose plates (EM Science, Gibbstown, NJ) chro- 
matographed in 0.55 M ammonium sulfate. Analysis of the 
plates using a Molecular Dynamics PhosphorImager (Sun- 
nyvale, CA) revealed > 95% radioactivity remained at the 
origin with the oligonucJeotide. 
2.7. Biodistribution studies 
t~Jin_DTPA_SA_labeled liposomes, without or with 
complexed ~'-SI-labeled oligonucleotide, were injected 
(0.500 mg of lipid, unless indicated otherwise, in 200 p~l) 
into female CD-1 mice (6-8-week-old) via the tail vein. At 
the indicated time interval, the mice were anesthetized, 
weighed, and bled by retroorbital puncture. The mice were 
killed by cervical dislocation and dissected. In addition to 
blood, organs were collected, weighed, and analyzed for 
~ In  radioactivity in a gamma counter. For dual-label 
studies, channel windows were set to collect J l J In and 1251 
cpm individually, and cross-talk was accounted for appro- 
priately. The results are presented as percent of the total 
injected dose for each organ. The total radioactivity in 
blood was determined by assuming the total blood volume 
was 7.3% of the body weight [14]. Blood correction factors 
for each organ were determined as described [15] for 
female CD- 1 mice of the same age and weight. Approx. 4, 
8, and 1% of the total blood remained in the lung, liver, 
and spleen, respectively, following bleeding. 
2.8. Immuno-histochemistr 3, 
For immuno-histochemistry and immuno-electron mi- 
croscopy, tissues from mice injected with cationic lipo- 
some/oligonucleotide F15-27 complex (830 /xg of lipid in 
400 /xl) i.v. via the tail vein were collected at 15 rain and 
24 h post-injection. The mice were killed by cervical 
dislocation and the lungs were inflated in situ with 4% 
paraformaldehyde in 0.1 M phosphate buffer (PB), pH 7.4, 
then excised and immersed in the fixative. The livers were 
removed whole, then thinly sliced, and immersion fixed. 
Small blocks of the lung and liver were further processed 
for immuno-electron microscopy (see below). The remain- 
ing lung and liver samples were rinsed overnight in PB 
buffer and then processed into paraffin. Tissue sections cut 
at 3 /xm were deparaffinized and hydrated into PBS, then 
pretreated with 0.1% proteinase for 1 min and with 2 N 
HCI for 1 h at room temperature. After thorough washing 
with distilled water, sections were incubated with rat mon- 
oclonal antibody F4/80 (Harlan, Indianapolis, IN), an 
antibody which binds to mouse macrophage [16], or iso- 
type control at a concentration of 200 /xg/ml. Primary 
antibody was detected by using ABC reagents from BioTek 
for peroxidase immuno-histochemistry with diaminobenzi- 
dine as brown chromagen. Sections were then incubated 
with rat anti-BrdU antibody (Accurate, Westbury, NY) or 
isotype control at a concentration of 1 /xg/ml for 45 rain. 
This antibody was subsequently detected using the ABC- 
alkaline phosphatase reagents and red chromagen from 
BioTek (Santa Barbara, CA). Sections were counterstained 
with hematoxylin, dehydrated, cleared, and coverslipped. 
2.9. Immuno-electron microscopy 
For immuno-electron microscopy, lung and liver blocks 
were fixed for 3 h. These specimens were subsequently 
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washed overnight in PB and dehydrated through a graded 
ethanol series and propylene oxide prior to infiltration in 
Medcast resin (Ted Pella, Redding, CA) and curing at 
60°C for 24 h. Ultrathin sections were cut and collected on 
nickel grids. The section faces were hydrated in PBS for 
30 min and incubated for 2 h with either rat anti-BrdU 
primary antibody (Dako, Carpenteria, CA) or an isotype 
control at a concentration of 33 ~g/ml  in a diluent 
consisting of 1% bovine serum albumin in PBS with 
0.05% Tween and 0.02% NaN 3. After washing three times 
in PBS, the tissues were blocked by incubating in 10% 
goat serum in diluent for 1 h. The sections were then 
directly reacted for 1 h with a 5% solution of 10 nm 
gold-goat anti-rat (GAR) secondary antibody conjugate 
(Amersham, Buckinghamshire, UK) in diluent. The sec- 
tions were rinsed in PBS, then in distilled water and 
subsequently contrast enhanced with aqueous uranyl ac- 
etate prior to examination on a Phillips CMI20 transmis- 
sion electron microscope. 
tions determined at 24 h post i.v. injection. No significant 
differences in biodistribution amongst he liposome com- 
positions were observed (Table 1). The injected liposomes 
accumulated primarily in liver (~ 74-82% of the injected 
dose). Accumulation in spleen (~ 4-8% of the injected 
dose) and skin (~ 3-5% of the injected dose) was also 
observed. Approx. 1% or less of the injected ose accumu- 
lated in lung. Thus, the majority of the injected lipid 
accumulated in liver. 
The uptake of injected cationic liposomes (DC- 
Chol/DOPE, 1:1, tool/tool) by liver was very rapid as 
shown in Fig. 2A. By 5 min post-injection, approx. 60% of 
the injected dose had accumulated in liver, while only 
approx. 18% of the injected dose remained in circulation. 
By 7.5 h post-injection liver uptake was saturated, where 
accumulation of approx. 85% of the injected dose was 
achieved. 
3.3. Effect c)f injection dose on cationic liposome biodistri- 
bution 
3. Results 
3.1. Analysis of  DTPA-SA in cationic liposomes 
DTPA-SA has been used extensively to monitor lipo- 
some biodistribution [10,11,15,17]. Before conducting 
cationic liposome biodistribution studies, DTPA-SA was 
examined for any influence on various properties of cationic 
liposomes. Increasing mol% of DTPA-SA was included in 
cationic liposomes (DC-Chol/DOPE, 1:1, mol/mol, and 
labeled with a trace amount of 3H-CE) to determine if this 
molecule influences liposome uptake by CHO cells. Fig. 
1A shows that inclusion of up to 5 mol% DTPA-SA in the 
lipid composition did not affect uptake. Furthermore, lipo- 
some formation and liposome size were not influenced by 
the added DTPA-SA (data not shown). Fusion of the 
cationic liposomes with endosomal/lysosomal embranes 
following uptake may play an important role in oligo- 
nucleotide delivery [12]. Inclusion of up to 5 tool% DTPA- 
SA in cationic liposomes labeled with Pyr-PC did not 
significantly influence lipid mixing following uptake by 
CHO cells, as monitored by decreasing excimer fluores- 
cence (Fig. 1B). Finally, inclusion of up to 5 mol% 
DTPA-SA in cationic liposomes did not influence nuclear 
delivery of FITC-labeled oligonucleotide to CHO cells 
(Fig. 1C-E). Therefore, because DTPA-SA did not affect 
cationic liposome formation, interaction with cells, or 
oligonucleotide delivery, this amphipathic helator was 
used as a lipid phase radiolabel for further investigations, 
where the concentration f DTPA-SA (labeled with a trace 
of u lIn) never exceeded 0.2 tool%. 
3.2. Biodistribution of  cationic liposomes 
Cationic liposomes with increasing positive charge (20- 
80 mol% DC-Chol) were prepared and their biodistribu- 
The injection dose of cationic liposomes (DC- 
Chol/DOPE, 1:1, tool/tool) was varied from 0.083 mg to 
1.670 mg of lipid in 200/~1, and the mice were killed at 24 
h post-injection. The results are presented in Fig. 3 as p.g 
of lipid accumulated per g of tissue, plotted against mg of 
lipid injected per kg weight of the mice. Liposome uptake 
in spleen and liver was directly proportional to the injected 
dose in the range of 0.083 to 0.833 mg per mouse, or 3.33 
to 33.33 mg/kg body weight. Within this range, spleen 
and liver accumulation were equally efficient. However, at 
an injection dose of 66.80 mg/kg body weight, the effi- 
ciency of the spleen uptake increased relative to that of 
liver uptake. Furthermore, the concentration of lipid in 
lung and blood slightly increased at the high doses. This 
effect may have resulted from saturation of the liver 
uptake mechanism(s) at the high dose, allowing opportu- 
nity for the liposomes to circulate longer and accumulate 
in other tissues. 
3.4. Effect of  serum on cationic liposome uptake in vitro 
Interaction of cationic liposomes with plasma compo- 
nents immediately following injection may hinder nonspe- 
cific binding with cell membranes and accumulation within 
tissues. This would explain for example the relatively low 
accumulation of cationic liposomes in lung, the first capil- 
lary bed encountered following tail vein injection. To 
explore the effects of plasma components, cationic lipo- 
somes were briefly preincubated in increasing concentra- 
tions of mouse serum, and the mixtures were subsequently 
added to CHO cells for 1 h incubation at 37°C. Fig. 4A 
shows that increasing concentration of serum blocked 
cationic liposome binding/uptake by CHO cells. The pres- 
ence of only 10% serum reduced uptake by 80% compared 
to serum-free incubations. Thus, components in the plasma 
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Fig. I. DTPA-SA does not affect properties ofcationic liposomes. (A) Binding/uptake of cationic liposomes by CHO cells is unaffected by DTPA-SA. 
DC-Chol/DOPE liposomes with increasing concentration of DTPA-SA, and labeled with 3H-CE, were incubated with CHO cells for 1 h at 37°C. The 
liposome concentration n each sample was 80/~M. The cells were then washed, lysed, and radioactivity and protein concentration assayed as described in
Materials and methods. The data represent the mean _+ S.D. for samples assayed in triplicate. (B) Fusion of cationic liposomes with CHO cells is 
unaffected by DTPA-SA. Lipid mixing between DC-Chol/DOPE liposomes, with 5 tool% Pyr-PC and 0.0 ([]), 0.2 (~), 1.0 (O), 2.5 (A), and 5.0 ('7) 
mot% DTPA-SA, and trypsinized CHO cells at 37°C was assayed as described in Section 2. (C-E) Delivery of oligonucleotide to cells by cationic 
liposomes i unaffected byDTPA-SA. DC-Chol/DOPE liposomes with 0.0 (C), 2.5 (D), and 5.0 (E) tool% DTPA-SA, and complexed with FITC-labeled 
oligonucleotide, were incubated with CHO cells grown on coverslips for 1 h at 37°C. The liposome concentration n each sample was 100 p.M. The cells 
were then washed, fixed, and photographed as described inSection 2. 
may indeed hinder nonspecific binding of cationic lipo- 
somes to cells. 
3.5. Biodistribution of cationic liposome / oligonucleotide 
complex 
Dual-radiolabeled cationic l iposome/oligonucleotide 
complex was prepared by adding oligonucleotide, labeled 
with a trace of mSI-oligonucleotide, to ll~In-DTPA-SA- 
labeled cationic liposomes. The size of the complex was 
approx. 1828 + 24 nm (polydispersity = 0.36) as measured 
by light-scattering, compared to a measured size of 65 + 1 
nm (polydispersity = 0.25) for the liposomes before addi- 
tion of oligonucleotide (data not shown). The biodistribu- 
tion of the complex injected i.v., following the lipid label, 
and compared to that of liposomes without added oligo- 
nucleotide, is shown in Fig. 2B. Complexation with oligo- 
nucleotide induced a dramatic and transient accumulation 
of lipid in lung. At 5 min post-injection, ~ 80% of the 
injected dose of the complexed lipid was present in lung 
compared to ~ 10% of the injected dose for liposomes 
without added oligonucleotide. This accumulated lipid 
gradually redistributed to liver where by 18 h post-injec- 
tion, approx. 4% and 82% of the injected dose of lipid 
were present in lung and liver, respectively. 
The biodistribution of the complex following the oligo- 
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Table 1 
Biodistribution of cationic liposomes at 24 h post-injection ~
Tissue % Injected dose 
DOPE/DC-Chol (mol/mol): 4:1 2:1 1:1 1:2 1:4 
Blood b 0.38 (0.07) 0.35 (0.11 ) 0•40 (0.04) 0.41 (0.12) 0.35 (0.06) 
Heart 0.08 (0.01) 0.06 (0.02) 0.08 (0.01 ) 0.08 (0.02) 0.08 (0.01 ) 
Thymus 0.04 (0.01) 0.04 (0.03) 0.03 (0.03) 0.04 (0.03) 0.02 (0.03) 
Lung 0.48 (0.09) 0.65 (0.13) 0.92 (0.21 ) 0.76 (0.11 ) 1.13 (0.15) 
Liver 74.17 (5.80) 77.43 (1.46) 82.18 (1.11) 75.89 (6•68) 77.65 (0.64) 
Kidney 0.75 (0.11 ) 0.68 (. 10) 0.82 (0.15) 0.67 (0.13) 0.68 (0•06) 
Spleen 7.77 (2.04) 6.35 (1•69) 4.55 (0.84) 3.92 (0.73) 4.67 (1.28) 
Stomach 0.70 (0.96) 0.25 (0.13) 0.21 (0•02) 1.43 (2.21) 0.12 (0.03) 
Intestine 1.40 (0.36) 1.72 (0.11 ) 2.12 (0.52) 2.30 (0.15) 1.89 (0.40) 
Pancreas 0.04 (0.01 ) 0.09 (0.10) 0.08 (0.05) 0.15 (0.15) 0.10 (0•06) 
Lymph nodes ~ 0.00 (0•01) 0.00 (0.01) 0.01 (0.02) 0.04 (0.03) 0.01 (0.01) 
Bone marrow n.d. d n.d. n.d. n.d. n.d. 
Uterus 0.06 (0.02) 0.07 (0.04) 0.08 (0.02) 0.14 (0.07) 0.18 (0.05) 
Ovaries 0.03 (0.01 ) 0.03 (0.01 ) 0.03 (0.01 ) 0.09 (0.05) 0.07 (0.06) 
Skeletal muscle ~ 0.80 (0.20) 0.99 (0.35) 0.74 (0.24) 0.92 (0.13) 1.14 (0.43) 
Skin f 3.29 (0.66) 4.54 (2.67) 3.13 (0.15) 3.39 (0.30) 4.33 (0.71 ) 
Brain 0.01 (0.02) 0.02 (0.01) 0.02 (0.02) 0.01 (0.01) 0.07 (0.04) 
Tail (injection site) 0.43 (0.16) 0.46 (0.11 ) 0.43 (0.11 ) 0.50 (0.11 ) 0.51 (0.19) 
% recovery ~ 90.42 (2.52) 93.74 (3.51 ) 95.84 (0.97) 90.73 (3.29) 92.99 (1.56) 
Cationic liposomes prepared by sonication, with increasing concentration of DC-Chol, and labeled with ~]Iln-DTPA-SA were injected i.v. (500 /zg of 
lipid in 200 /xl) into CD-1 mice. Percent injected dose was measured 24 h post-injection. Numbers in parentheses are S.D. (n = 3). 
b Calculated from collected blood and assuming that 7.3% of the total body weight is blood [14]. 
Only mesenteric lymph nodes were collected. 
d Not detected. 
Calculated from collected muscle from the hind legs and assuming that 50% of the total body weight is muscle [18]. 
f Calculated from skin collected from the abdomen and neck, and assuming that 11% of the total body weight is skin [18]. 
(Sum of cpm from collected tissues divided by injected cpm)× 100. 
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Fig. 2. Time-course for biodistribution of cationic liposomes and cationic 
liposome/oligonucleotide complex. DC-Chol/DOPE liposomes labeled 
with I]IIn_DTPA_SA and without (A) or with (B) complexed oligo- 
nucleotide (cationic lipid/nucleotide charge ratio =4:1) were injected 
i.v. (0.500 mg of lipid in 200 /zl). Percent injected dose in blood (©), 
liver (O), spleen (zx), and lung (D)  was measured at the indicated time 
intervals. Bars represent S.D. (n = 3). 
nucleotide label was similar to the results obtained follow- 
ing the lipid label• Again, an immediate yet transient 
accumulation in lung was observed (Fig. 5A). However, 
the recovery of radioactivity was comparatively less than 
that from the lipid label and may be attributed to instability 
of the iodine label. The accumulation of the oligonucleo- 
tide in liver appears to plateau at 3 h post-injection. This 
2000 j 
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Fig. 3. Effect of injection dose on cationic liposome biodistribution. 
Various doses of DC-Chol/DOPE liposomes labeled with ]l I In-DTPA- 
SA were injected i.v. in a volume of 200 Ixl and the percent injected ose 
in blood (©), liver (O), spleen (zx), and lung (D) measured at 24 h 
post-injection. Bars represent S.D, (n = 3). The results are expressed as 
gg  of lipid accumulated per g of tissue weight. 
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apparent plateau however may reflect metabolism of the 
labeled oligonucleotide. Indeed, a transient increase of 
label present in intestine peaked at 3 h post-injection, 
followed by an increased appearance of label in feces (Fig. 
5B). Excretion of label in urine was also observed. There- 
fore, the liver accumulation of the liposome/oligonucleo- 
tide complex likely increased beyond 3 h post-injection, as 
revealed following the relatively nonmetabolizable lipid 
label [17]. 
We speculate that following injection, the complex 
accumulates rapidly in lung due to embolism. For oligo- 
nucleotide injected without complexed lipid, approx. 0.7% 
of the injected ose accumulated in lung at 15 rain post-in- 
jection (data not shown), suggesting that the oligonucleo- 
tide did not actively target he complex to lung. We further 
speculate that interaction with plasma components inhibits 
cellular uptake of the complex in lung. The complex is 
then slowly released from lung, perhaps caused by the 
flow of blood, and is immediately removed from the 
circulation by the liver. This immediate removal, perhaps 
mediated by bound opsonin(s), is indicated by lack of 
appearance of lipid in the blood, and the inverse pharma- 
cokinetic relation of tung and liver accumulation (Fig. 2B). 
200. 
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Fig. 4. Effect of serum on binding/uptake of cationic liposomes and 
cationic liposome/oligonucleotide complex by CHO cells. CHO cells 
were incubated with 3H-CE-labeled DC-Chol/DOPE liposomes, without 
(A) or with (B) complexed oligonucleotide (cationic lipid/nucleotide 
charge ratio = 4:1), in the presence of increasing concentration f mouse 
serum for 1 h at 37°C. The concentration f tiposomes added to each well 
was 80 /~M. The cells were then washed, and cpm and protein concentra- 
tion in each well determined. The data represent the mean+S.D, for 
samples assayed in triplicate. 
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Fig. 5. Biodistribution of oligonucleotide complexed with cationic lipo- 
somes. Liposomes complexed with oligonucleotide (cationic 
lipid/nucleotide charge ratio = 4:1, oligonucleotide labeled with a trace 
amount of J25I-oligonucleotide) were injected i.v. (0.500 mg of lipid and 
0.031 mg oligonucleotide in 200 /~1). Percent injected ose in (A) lung 
([3), liver (O), and blood (~),  and (B) kidney (~), stomach (O), 
intestine ([3), feces (z~), urine (v) ,  and thyroid (5~, 24 h only) was 
measured at the indicated time intervals. Bars represent S.D. (n = 3). 
3.6. Effect ~)f serum on cationic" liposome / oligonucleotide 
complex uptake in vitro 
To test the hypothesis that plasma components inhibit 
cellular uptake of the cationic liposome/oligonucleotide 
complex, the complex was briefly preincubated with in- 
creasing concentration of mouse serum, and the mixtures 
were subsequently added to CHO cells for 1 h incubation 
at 37°C. The presence of only 20% mouse serum was 
sufficient o reduce binding/uptake of the complex by 
81% compared to serum-free incubations (Fig. 4B). A 
higher concentration of serum however was required to 
inhibit binding/uptake of the complex compared to 
cationic liposomes without added oligonucleotide (Fig. 
4A). These results nonetheless upport he hypothesis that 
plasma components inhibit cellular uptake of the complex. 
3.7. Tissue distribution of" cationic liposome / oligonucleo- 
tide complex 
The distribution of the cationic liposome/oligonucleo- 
tide complex within lung and liver at 15 min and 24 h post 
i.v. injection is shown in Fig. 6. BrdU-labeled oligonucleo- 
tide in the tissue sections was stained using anti-BrdU 
antibody and alkaline phosphatase-conjugated secondary 
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Fig. 7. Localization of liposome/oligonucleotide complex accumulated in tissues as determined byimmuno-electron microscopy. Mice were injected with 
cationic liposome/oligonucleotide F15-27 complex (cationic lipid/nucleotide charge ratio = 4:1,830/zg of lipid in 400 /zl injected) i.v. via the tail vein. 
Tissues were harvested and processed asdescribed inSection 2. The BrdU-labeled oligonucleotide was stained with rat anti-BrdU antibody and gold-GAR 
secondary antibody conjugate. The sections were contrast enhanced with aqueous uranyl acetate. (A) Lung section from mouse killed at 15 min 
post-injection. (B and C) Liver section from mouse killed at 24 h post-injection. Arrow in (A) indicates uptake of oligonucleotide into vacuoles of 
macrophage. Arrow in (C) indicates presence of oligonucleotide in lysosome of hepatocyte. Nu. nucleus: L, lumen: sd, space of Disse; and bc. bile 
canaliculis. Bars in (A-C) correspond to 0.5 /.tin. 
antibody with red chromagen. Fig. 6A reveals large aggre- 
gates of oligonucleotide within the alveolar septa at 15 rain 
post-injection. By 24 h post-injection, the degree of stain- 
ing within lung sections decreased, with fewer aggregates 
and which were of smaller size remaining (Fig. 6B). These 
results support embolism as the mechanism by which the 
injected complex accumulates rapidly in lung following 
injection. Furthermore, the staining intensities of the lung 
and liver sections (see below) correspond to the quantita- 
tive results obtained from the radiolabel studies. Staining 
of macrophage in the lung sections with the brown chro- 
magen is difficult to discern at the magnification shown. 
Fig. 6C shows the distribution of Kupffer cells, stained 
with brown chromagen, within the liver section from a 
mouse sacrificed at 15 min post-injection. Discernible 
staining of the oligonucleotide was difficult to detect at 
this early time point. By 24 h post-injection, liver accumu- 
lated oligonucleotide was localized primarily to Kupffer 
cells, where co-localization of stains was observed (Fig. 
6D). Higher magnification revealed oligonucleotide accu- 
mulated within Kupffer cells to be present in the cyto- 
plasm (Fig. 6D, inset), and not in the nucleus. A detectable 
amount of oligonucleotide however was present in non- 
macrophage cells (Fig. 6D). 
Distribution of the injected cationic l iposome/oligo- 
nucleotide complex within lung and liver was further 
evaluated by immuno-electron microscopy (Fig. 7). BrdU- 
labeled oligonucleotide in tissue sections was stained with 
rat anti-BrdU antibody and gold-GAR secondary antibody 
conjugate. At 15 min post-injection, oligonucleotide accu- 
mulated in lung was localized primarily to the lumen of 
pulmonary capillaries (Fig. 7A). Oligonucleotide was also 
occasionally present within phagocytic vacuoles of 
macrophage in the lung (Fig. 7A). These results give 
further support for embolism as a mechanism for early 
lung accumulation of the injected complex. 
In liver, oligonucleotide was abundantly present in 
phagocytic vacuoles of Kupffer cells at 24 h post-injection 
Fig. 6. Localization of liposome/oligonucleotide complex accumulated in tissues as determined by immuno-histochemistry. Mice were injected with 
cationic liposome/oligonucleotide F15-27 complex (cationic lipid/nucleotide charge ratio = 4:1. 830 #g of lipid in 400 ~1 injected) i.v. via the tail vein. 
Tissues were harvested and processed asdescribed in Section 2. The BrdU-labeled oligonucleotide was stained with anti-BrdU antibody and alkaline 
phosphatase-conjugated secondary antibody with red chromagen. Macrophage in tissue sections were stained with monoclonal ntibody F4/80 and 
peroxidase-conjugated secondary antibody with diaminobenzidine as a brown chromagen. Tissue sections were counterstained with hematoxylin. (A and B) 
Lung sections from mice sacrificed at 15 min (A) and 24 h (B) post-injection. Bar in (A) corresponds to 100 /zm for lung sections. (C and D) Liver 
sections from mice killed at 15 rain (C) and 24 h (D) post-injection. Bar in (C) corresponds to 50 /~m for liver sections. Arrow and arrowhead in(D) 
indicate presence ofoligonucleotide n a Kupffer cell and a nonmacrophage cell, respectively. (D, inset) Liver section prepared as in (D) viewed at high 
magnification. Arrow in (D, inset) indicates presence ofoligonucleotide within Kupffer cells. 
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(Fig. 7B). Oligonucleotide was also infrequently found 
within lysosomes of hepatocytes (Fig. 7C). Immuno-elec- 
tron microscopy did not reveal any notable presence of 
oligonucleotide in nuclei of lung or liver cells. Further- 
more, presence of oligonucleotide within endothelial cells 
of these tissues was not detected. 
4. Discussion 
We have used DTPA-SA as a lipophilic radiolabel to 
evaluate the biodistribution of cationic liposomes in mice 
following intravenous injection. This amphipathic helat- 
ing agent consists of DTPA covalently attached to two 
stearyl chains via amide bonds [19]. It has previously been 
demonstrated that this radiolabel is not transferred toserum 
components from liposomes [19], and is not rapidly metab- 
olized in vivo [17]. The negative charge contributed by this 
amphipathic helator, with three carboxylic acid groups 
per molecule, might be expected to interfere with the 
formation and activity of cationic liposomes. However, we 
have shown here that this label, at concentrations of up to 
5 mol%, does not interfere with properties of cationic 
liposomes, including oligonucleotide delivery. 
The clearance of positively charged SUVs containing 
stearylamine (SA) has previously been shown to be similar 
to that of neutral iposomes, and less rapid than negatively 
charged liposomes with phosphatidylserine (PS) in the 
lipid composition [20]. However, issues concerning re- 
moval of the positively charged SA component following 
injection, thus leading to uncharged vesicles were pre- 
sented [21]. Clearance of liposomes which retain their 
positively charged lipid component may be through inter- 
action with the negative surface charge of cells and/or 
interaction with negatively charged plasma components, 
including opsonin(s). We have demonstrated here that the 
presence of serum blocks the binding/uptake of DC- 
Chol-containing vesicles by cells in vitro. Furthermore, the 
liposomes did not accumulate significantly in lung, sug- 
gesting binding/uptake by endothelial cells of the lung 
was inhibited by plasma components. It has been shown 
that positively charged liposomes assume an overall nega- 
tive charge in the presence of plasma [22], which may be 
contributed by bound negatively charged plasma protein. 
We therefore speculate that clearance of DC-Chol vesicles, 
by the reticuloendothelial system, is primarily mediated via 
rapidly bound protein, including opsonin(s). To determine 
whether there is any significant ransfer of DC-Chol from 
the vesicles to serum components, however, requires fur- 
ther investigation. 
The cationic liposome/oligonucleotide complex 
demonstrated a dramatic, yet transient accumulation in 
lung after injection, as revealed following both radiola- 
beled lipid and oligonucleotide. Because the lipid label is 
not rapidly metabolizable [17], these data indicate the loss 
of accumulated radioactivity from the lung is not due to 
secretion of endocytosed and metabolized label. We specu- 
late that the complex was not readily endocytosed by lung 
cells, except for a small portion by lung macrophage, and 
was accumulated by embolism. We have shown that serum 
blocks binding/uptake of the cationic liposome/oligo- 
nucleotide complex by CHO cells in vitro. The molar 
charge ratio of DC-Chol to nucleotide in the present 
studies was 4:1, allowing for residual positive charge for 
efficient oligonucleotide delivery (D. Collins, unpublished 
data). Electrostatic attraction of negatively charged plasma 
components to the complex may have in turn inhibited 
interaction of the complex with cells. Interestingly, a
greater concentration of serum was required to inhibit 
binding/uptake of the complex compared to cationic lipo- 
somes without oligonucleotide. One possible xplanation is 
that while a reduction in positive charge upon complexa- 
tion with oligonucleotide r duced lipid uptake in the ab- 
sence of serum, the complexation furthermore r duced the 
electrostatic attraction of serum components. Size mea- 
surements of the complex, before injection, by light- 
scattering routinely revealed average diameters of approx. 
2 /xm. Furthermore, the size and stability of the complex 
may be modified following injection. A sufficiently large 
size/aggregation f the complex would allow for physical 
trapping in the pulmonary capillaries as emboli. The de- 
gree to which serum-complex interaction may contribute to 
the actual aggregation/embolization requires further char- 
acterization. While bound serum components may have 
inhibited cellular uptake of the complex, these components 
may have included opsonin(s) to mediate the rapid clear- 
ance, primarily by Kupffer cells of the liver, following 
release from the lung. 
As demonstrated here, a small portion of oligonucleo- 
tide accumulated in liver at 24 h was detected in the 
lysosomes of hepatocytes. To determine why these cells 
endocytosed oligonucleotide yet did not reveal detectable 
nuclear delivery requires further investigation. Overall, it 
must be noted that by our immuno-histochemistry and 
immuno-electron microscopy methods, nuclear delivery of 
oligonucleotide by cationic liposomes in vivo was not 
detected. This includes nuclear delivery to hepatocytes and 
macrophages of the liver and macrophages of the lung 
which accumulated oligonucleotide, aswell as for endothe- 
lial cells where even uptake of oligonucleotide was not 
observed. In other studies, our methods have successfully 
demonstrated accumulation of oligonucleotide in the nuclei 
of smooth muscle cells when administered to injured arter- 
ies [23]. 
From these studies we propose that interaction with 
plasma components presents a major hurdle for efficient 
oligonucleotide delivery by cationic liposomes in vivo. 
This interaction may inhibit cellular binding/uptake and 
furthermore mediate rapid clearance by Kupffer cells. By 
reducing the interaction of plasma components with the 
injected complex, these barriers to oligonucleotide livery 
via cationic liposomes may be overcome. 
D. C. Litzinger et aL / Biochimica et Biophysica Acta 1281 (1996) 139-149 149 
References 
[1] Akhtar, S. and Juliano, R.L. (1992) Trends Cell Biol. 2, 139-144. 
[2] Fisher, T.L., Terhorst, T., Cao, X. and Wagner, R. W. (1993) 
Nucleic Acids Res. 21, 3857-3865. 
[3] Agrawal, S., Temsamani, J. and Tang, J.Y. (1991) Proc. Natl. Acad. 
Sci. USA 88, 7595-7599. 
[4] Wagner, R.W. (1994) Nature 372, 333-335. 
[5] Bennett, C.F.. Chiang, M.Y., Chan, H., Shoemaker, J.E. and 
Mirabelli, C.K. (1992)Mol. Pharmacol. 41, 1023-1033. 
[6] Colige, A., Sokolov, B.P., Nugent, P., Baserga, R. and Prockop, D.L 
(1993) Biochemistry 32, 7-11. 
[7] Gao, X. and Huang, L. (1991) Biochem. Biophys. Res. Commun. 
179, 280-285. 
[8] Plautz, G.E., Yang, Z.Y., Wu, B.Y., Gao, X., Huang, L. and Nabel, 
G.J. (1993) Proc. Natl. Acad. Sci. USA 90, 4645-4649. 
[9] Kabalka, G.W., Buonocore, E., Hubner, K., Moss, T., Norley, N. 
and Huang, L. (1987) Radiology 163, 255-258, 
[10] Maruyama, K., Kennel, S.J. and Huang, L. (1990) Proc. Natl, Acad. 
Sci. USA 87, 5744-5748. 
[11] Litzinger, D.C., Buiting, A.M.J., Van Rooijen, N. and Huang, L. 
(1994) Biochim. Biophys. Acta 1190, 99-107. 
[12] Wrobel. I. and Collins, D. (1995) Biochim. Biophys. Acta 1235, 
296-304. 
[13] Piatyszek, M.A., Jarmolowski, A. and Augustyniak, J. (1988) Anal. 
Biochem. 172, 356-359. 
[14] Wu, M.S., Robbins, J.C., Bugianesi, R.L., Ponpipom, M.M. and 
Shen, T.Y. (1981) Biochim. Biophys. Acta 674, 255-258. 
[15] Litzinger, D.C. and Huang L. (1992) Biochim. Biophys. Acta 1104, 
179-187. 
[16] Austyn, J.M. and Gordon, S. (1981) Eur. J. Immunol. 11,805-815. 
[17] Holmberg, E., Maruyama, K., Litzinger, D.C., Wright, S., Davis, 
M., Kabalka, G. W., Kennel, S.J. and Huang, L. (1989) Biochem. 
Biophys. Res. Commun. 165, 1272-1278. 
[18] Burka, L.T., Sanders, J.M,, Kool, C.P., Kim, Y.S. and Mathews, 
H.B. (1987) Toxicol. Appl. Pharmacol. 87, 121-126. 
[19] Kabalka, G.W., Davis, M.A., Moss, T.H., Buonocore, E., Hubner, 
K., Holmberg, E., Maruyama, K. and Huang, L. (1991) Magn. 
Reson. Med. 19, 406-415. 
[20] Juliano, R.L. and Stamp, D. (1975) Biochem. Biophys. Res. Com- 
mun. 63, 651-658. 
[21] Tan, L. and Gregoriadis, G. (1989) Biochem. Soc. Trans. 17, 
690-691. 
[22] Black, C. and Gregoriadis, G. (1976) Biochem. Soc. Trans. 4, 
253-256. 
[23] Farrell, C.L., Bready, J. V., Kaufman, S., Qian, Y. and Burgess, 
T.L. (1995) Antisense Res. Dev., in press. 
